Multiple Myeloma | Specialty

Proteasome Inhibitors Paving Promising Path for Myeloma Treatment

July 17th 2017

Kenneth H. Shain, MD, discusses the emergence of proteasome inhibitors in multiple myeloma and whether these agents will be best used as monotherapy or in combination regimens.

Myeloma Trial Explores Optimal Induction, Maintenance Regimens

July 17th 2017

Two combination regimens anchored by different proteasome inhibitors are being compared in a national clinical trial for patients with newly diagnosed symptomatic multiple myeloma that also seeks to evaluate the ideal duration of lenalidomide (Revlimid) maintenance therapy.

Amgen Files sNDAs for Carfilzomib to Treat Multiple Myeloma in Europe, US

July 14th 2017

Amgen has announced that it has submitted supplemental New Drug Applications (sNDA) in the United States and Europe based on data from 2 phase III studies showing carfilzomib (Kyprolis) improves overall survival (OS) for patients with relapsed/refractory multiple myeloma.

Carfilzomib Combo Extends Survival for Myeloma in Final ASPIRE Analysis

July 13th 2017

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone reduced the risk of death by 21% compared with lenalidomide and dexamethasone alone for patients with relapsed multiple myeloma.

Dr. Voorhees on Pivotal Ongoing Trials in Multiple Myeloma

July 12th 2017

Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses pivotal ongoing clinical trials in the field of multiple myeloma.

FDA Places Clinical Hold on 3 Pembrolizumab Myeloma Trials

July 6th 2017

The FDA has placed a clinical hold on the phase III KEYNOTE-183 and KEYNOTE-185 pembrolizumab (Keytruda) trials and ordered the discontinuation of the lenalidomide/dexamethasone/pembrolizumab arm of the KEYNOTE-023 trial in patients with multiple myeloma.

Dr. Kumar Discusses Ixazomib in Multiple Myeloma

July 5th 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses ixazomib (Ninlaro) in multiple myeloma.

Dr. Kumar Discusses Advances in the Field of Multiple Myeloma

June 29th 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses advances in the field of multiple myeloma.

Comparison of Induction Therapies Prior to ASCT Favors Novel Quadruple Over Triplet Regimens

June 24th 2017

Results from the phase III Myeloma XI study showed that patients with myeloma had deeper responses after induction and after allo-stem cell transplantation with outpatient-delivered quadruplet therapy than with sequential immunomodulatory triplet combinations.

Ixazomib Maintenance Shows Robust Activity in Multiple Myeloma

June 24th 2017

Patients with newly-diagnosed multiple myeloma who did not elect to undergo stem cell transplant but remained on single agent ixazomib maintenance fared as well as those who received SCT.

Response Rate Hits 100% for bb2121 in Multiple Myeloma

June 23rd 2017

All patients with multiple myeloma in a phase I study showed a response following treatment with an active dose of bb2121, an investigational anti–BCMA CAR T-cell construct.

Future Directions in Multiple Myeloma

June 21st 2017

Emerging Agents for Multiple Myeloma

June 21st 2017

CAR T-Cell Therapy for Multiple Myeloma

June 21st 2017

Immunotherapy for Multiple Myeloma

June 21st 2017

Sequencing Therapies in Multiple Myeloma

June 21st 2017

Continuing IMiD Therapy after Myeloma Relapse

June 21st 2017

Antibodies for Relapsed/ Refractory Multiple Myeloma

June 21st 2017

Maintenance Therapy for Multiple Myeloma

June 21st 2017

Optimal Timing for Transplantation in Myeloma

June 21st 2017